{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:46:56Z","timestamp":1790729216489,"version":"4.1.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options and poor prognosis. Epidermal growth factor receptor (EGFR) alterations, including amplifications, mutations, and fusions, are prevalent in GBM and represent potential therapeutic targets. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), has demonstrated efficacy in EGFR-mutated non-small cell lung cancer and central nervous system metastases. However, its efficacy in GBM remains uncertain. We present 2 cases of recurrent GBM harboring distinct EGFR alterations treated with osimertinib. Both patients, despite showing EGFR amplification or activating mutations (G719D), experienced rapid disease progression and clinical deterioration during treatment. These findings highlight the resistance of GBM to osimertinib, possibly due to tumor heterogeneity, subclonal variation, or intrinsic mechanisms linked to EGFR amplification and redundant oncogenic pathways. Our observations align with prior trials of EGFR-TKIs in GBM, which have shown limited benefit. These cases underscore the complexity of targeting EGFR in GBM and the need for advanced therapeutic approaches, including next-generation EGFR inhibitors and antibody-drug conjugates, to overcome resistance. Further studies are crucial to optimize EGFR-targeted therapies in GBM.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf146","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:06:56Z","timestamp":1753711616000},"source":"Crossref","is-referenced-by-count":4,"title":["Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib"],"prefix":"10.1093","volume":"30","author":[{"given":"Federico","family":"Villanacci","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Prost","sequence":"additional","affiliation":[{"name":"Inserm U1127, CNRS UMR 7225, Institut du Cerveau, ICM, Charles Foix, Service de Neuro-oncologie, Sorbonne Universit\u00e9, AP-HP, H\u00f4pitaux Universitaires la Piti\u00e9 Salp\u00eatri\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pieri","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Boetto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, H\u00f4pitaux Universitaires la Piti\u00e9 Salp\u00eatri\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Zucchi","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giusti","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord Ovest, Pathology Unit, Centro Polispecialistico \u201cAchille Sicari,\u201d Carrara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, AP-HP, H\u00f4pitaux Universitaires la Piti\u00e9 Salp\u00eatri\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Nichelli","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, AP-HP, H\u00f4pitaux Universitaires la Piti\u00e9 Salp\u00eatri\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Cupini","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Allegrini","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Della Porta","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio Santo","family":"Santonocito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-7799","authenticated-orcid":false,"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[{"name":"Inserm U1127, CNRS UMR 7225, Institut du Cerveau, ICM, Charles Foix, Service de Neuro-oncologie, Sorbonne Universit\u00e9, AP-HP, H\u00f4pitaux Universitaires la Piti\u00e9 Salp\u00eatri\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-0647","authenticated-orcid":false,"given":"Anna Luisa","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Azienda USL Toscana Nord-ovest, Livorno Hospital , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2025072810065031500_CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100884","article-title":"RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties","volume-title":"Translational Oncology","author":"Ah-Pine","year":"2021"},{"key":"2025072810065031500_CIT0002","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"2025072810065031500_CIT0003","doi-asserted-by":"publisher","first-page":"100884","DOI":"10.1016\/j.tranon.2020.100884","article-title":"RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties","volume-title":"Transl. Oncol.","author":"Ah-Pine","year":"2021"},{"key":"2025072810065031500_CIT0004","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discovery"},{"key":"2025072810065031500_CIT0005","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-20-0103","article-title":"Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical nsclc models harboring the uncommon EGFR mutations G719X or L861Q or S768I","volume":"19","author":"Floch","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025072810065031500_CIT0006","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11060-021-03834-3","article-title":"Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation","volume":"154","author":"Cardona","year":"2021","journal-title":"J Neurooncol"},{"key":"2025072810065031500_CIT0007","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/CRST.CRST_27_19","article-title":"Osimertinib in G719A mutated non-small cell lung cancer with leptomeningeal metastases","volume":"2","author":"Pandey","year":"2019","journal-title":"Cancer Res. Stat. Treat"},{"key":"2025072810065031500_CIT0008","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol Cancer"},{"key":"2025072810065031500_CIT0009","doi-asserted-by":"crossref","first-page":"vi82","DOI":"10.1093\/neuonc\/nox168.338","article-title":"EXTH-46. A precision medicine approach to target EGFRvIII in GBM: osimertinib (AZD9291) inhibits the growth of egfrviii-positive glioblastoma stem cells and increases survival of mice bearing intracranial EGFRvIII-positive GBM","volume":"19","author":"Kwatra","year":"2017","journal-title":"Neuro Oncol"},{"key":"2025072810065031500_CIT0010","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/2159-8290.CD-13-0879","article-title":"EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing","volume":"4","author":"Francis","year":"2014","journal-title":"Cancer Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf146\/63862851\/oyaf146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf146\/63862851\/oyaf146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:06:56Z","timestamp":1753711616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf146\/8215211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf146","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf146"}}